An implantable medical device configured to selectively permit access to a medicament reservoir or fluid pathway by way of at least one contactless key, including an implantable medical device having a medicament reservoir fluidly coupled to an access port via a first conduit and a second conduct via an access valve, and at least one contactless key configured to impart a magnetic field upon a portion of the implantable medical pump to manipulate the access valve between a first position fluidly coupling the medicament reservoir to the access port via the first conduit, and a second position fluidly coupling the medicament reservoir to the access port via the second conduit, and a third position isolating the medicament reservoir from the access port.

A power injectable port assembly for use with a power injector system, including a power injectable port. The power injectable port can include a body formed from a bio-compatible plastic material, and can include a cap and a base. A septum is captured between the cap and the base and is accessible through an opening in the cap. The base can define a cavity and the septum can be positioned over the cavity. The base can include a lower surface with a radiopaque identification feature observable via imaging technology subsequent to subcutaneous implantation of the power injectable port.

An access port for providing subcutaneous access to a patient is disclosed. In one embodiment, the port includes an internal body defining a fluid cavity that is accessible via a septum. A compliant outer cover including silicone is disposed about at least a portion of the body. A flange is included with the port body and is covered by the outer cover. The flange radially extends about a perimeter of the port body proximate the septum so as to impede penetration of a needle substantially into the outer cover in instances where the needle misses the septum. The flange can further include both an anchoring feature for securing the outer cover to the port body and an identification feature observable via x-ray imaging technology for conveying information indicative of at least one attribute of the access port. The outer cover provides a suitable surface for application of an antimicrobial/antithrombotic coating.

Endovascular drug delivery systems and methods are disclosed herein for delivering a therapeutic agent to the intracranial subarachnoid space of a patient, and/or deploying an endovascular drug delivery device distal portion in the intracranial subarachnoid space and a portion of the drug delivery device body in a dural venous sinus such that a therapeutic agent is delivered from the deployed drug delivery device into the intracranial subarachnoid space.

Fluid delivery systems and methods of delivering an agent and treating a disorder are disclosed that include a subcutaneously implantable port having a body defining a chamber with an open top and a delivery opening and a septum coupled to the body to extend over the open top of the chamber. The systems and methods can further include an intrathecal catheter having an proximal end configured to be coupled to the port and fluidly coupled to the delivery opening of the chamber and a plug having a body with a passage to receive the intrathecal catheter therethrough. The plug can be configured to be inserted into the fascia to protect against leakage of cerebrospinal fluid.

A venous access port assembly having a housing base with a discharge port, a septum, and a cap, with an interior reservoir. The housing base is provided with X-ray discernable indicia to identify an attribute of the assembly after its implantation and clearly appear on an X-ray of the patient in a manner informing the radiologist or technologist and the medical practitioner of that particular attribute. Such indicia can be depicted as cutouts through a disc of radiopaque material where the cutouts are in the form of alphabetical letters such as “CT”, or can be a set of discrete elements of radiopaque material, that are affixed along the bottom surface of the housing base or embedded within the thickness of the bottom housing wall.

Method of safely refilling an implanted infusion pump. The method includes contacting a withdrawn fluid with a protein-detecting composition, detecting whether the protein-detecting composition experiences a reaction, and performing a refilling procedure if no reaction is detected.

A method of printing radiopaque indicia on a medical device. The method includes applying radiopaque marking fluid to a surface of a plate comprising one or more etchings having a depth of at least 0.0001 inches, exposing the radiopaque marking fluid on the surface of the plate to air to allow the radiopaque marking fluid to achieve a sufficient level of tackiness, and transferring the radiopaque marking fluid to a medical device. The radiopaque marking fluid comprises a clear ink and tungsten particulates having a particulate size of more than one micron.

An implantable portal includes a septum that has embedded therein an indicia adapted to identify at least one characteristic of the portal. The indicia may be formed as an impression at a base layer of the septum, and is filled with a radiopaque material. The septum base layer is covered by liquid silicone, which bonds with the septum base layer when solidified, so that an integral one-piece septum, with the identifier indicia embedded therein, is effected. The indicia embedded septum is fitted to the reservoir housing of the portal for providing identification information for that portal. The septum embedded indicia is viewable visually and also by x-ray or computer tomography imaging.

A power-injectable access port can include a power-injectable access port cap including an opening and a power-injectable access port base including a reservoir corresponding to the opening. The power-injectable access port can further include a septum corresponding to the reservoir. The septum can include a bottom surface covering the reservoir and a top surface extending through the opening in the power-injectable access port cap. The power-injectable access port can include a radiopaque identification feature indicating that the power-injectable access port is suitable for power injection. The radiopaque identification feature can be a suspension of a radiopaque material in a silicone material positioned on an outer surface of the power-injectable access port base. The radiopaque identification feature can have a thickness protruding from the outer surface of the power-injectable access port base such that it is perceivable by sight and touch prior to subcutaneous implantation of the power injectable access port.